Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2014

Trulicity(Dulaglutide)Eli Lilly and Company logoLLY

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Eli Lilly and Company

$5.45B

Medicare cost, 2024

Medicare drug plans spent $5.5 billion on Trulicity (dulaglutide) in 2024, for 4.3 million prescriptions and refills filled by 788,414 patients. It ranks 6th among all drugs by Medicare drug plan spending. Spending fell 26% from 2023 to 2024. California accounts for the most spending ($402.6 million, 7% of the total).

Medicare cost, 2024

$5.45B

-25.9% from 2023

Prescriptions

4.3M

$1,266.91 per claim

Patients

788K

216,578 prescribers

Total spending, 2024

$5.45B

$6,915.21 per patient

Questions and answers

How much does Medicare spend on Trulicity?

Medicare prescription drug plans paid $5.45B for Trulicity in 2024, for 4,303,409 prescriptions and refills to 788,414 patients (down 25.9% from 2023). The average cost per claim was $1,266.91.

Which state spends the most on Trulicity?

California had the highest Medicare cost for Trulicity in 2024: $402.6M for 323,595 claims, followed by New York ($397.6M).

Who prescribes Trulicity the most?

Carlos R Figueroa Nunez, endocrinology in San Juan, PR, had the highest Medicare cost for Trulicity in 2024: 3,098 claims costing $3.2M.

Who makes Trulicity?

Trulicity is made by Eli Lilly and Company (LLY), listed in the Medicare spending data as Eli Lilly & Co..

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Trulicity was $5.45B in 2024, after a high of $7.36B in 2023.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Trulicity, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Carlos R Figueroa Nunez San Juan, PREndocrinology3,098394$3.2M
Stella Ilyayeva Rego Park, NYInternal Medicine1,736340$2.0M
Eugenio Angueira-Serrano Miami, FLEndocrinology1,812365$1.9M
Carlos A Pla Fernandez Tampa, FLEndocrinology1,578207$1.6M
Jane Mayrin Philadelphia, PAEndocrinology1,481173$1.5M
Iraklii Buziashvili Brooklyn, NYEndocrinology1,227257$1.3M
Jamal Hammoud Flint, MIEndocrinology886231$1.3M
Jose M Garcia Mateo Ponce, PREndocrinology1,160153$1.2M
Farhad Farjoudi San Diego, CAEndocrinology736172$1.2M
Robert J Pearlstein Plymouth Meeting, PAInternal Medicine1,561186$1.1M
Jean C Pujals Kury Bayamon, PRInternal Medicine1,102152$1.1M
Nduche C Onyeaso Fayetteville, NCEndocrinology745173$1.1M
Phong H Bui Fountain Valley, CAInternal Medicine808131$1.1M
Joymon K Sebastian Dartmouth, MANurse Practitioner889161$1.1M
Natasha Rodriguez Chicopee, MAPhysician Assistant1,003182$1.1M
Miguel A Ariza Dracut, MAInternal Medicine804148$1.1M
Hemant T Thawani Grand Blanc, MIEndocrinology547130$988K
Mushtaq A Syed Indiana, PAInternal Medicine876185$972K
Ayman Elkadry Huntington, WVEndocrinology904188$965K
Monica G Robles Anniston, ALEndocrinology652158$953K
Anant Jeet Lorain, OHEndocrinology754144$952K
Joselito C Cabaccan San Jose, CAEndocrinology654148$949K
Jessica I Rosa Carolina, PREndocrinology781116$907K
Natallia Kleshchanka Staten Island, NYNurse Practitioner843191$903K
Ashutosh S Pareek Salem, MAEndocrinology511125$889K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022199,5144,609,369839,891$6.22B
2023219,8785,313,751938,286$7.36B
2024216,5784,303,409788,414$5.45B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Eli Lilly & Co.LLY logoLLY4,305,141$5.45B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
11
RxNorm concept IDs
1551295, 1551300, 1551304, 1551306, 2395777
Application numbers
BLA125469

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube